Matrix metalloproteinases: A tail of a frog that became a prince

Nature Reviews Molecular Cell Biology

Volumn 3, Issue 3, 2002, Pages 207-214

  Brinckerhoff, Constance E ^a   Matrisian, Lynn M ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR;

BIOCHEMISTRY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME STRUCTURE; HISTORY OF MEDICINE; HUMAN; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEUS; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HISTORY; PHYSIOLOGY;

ANURA;

ANIMALS; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTORY, 20TH CENTURY; HUMANS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEASE INHIBITORS;

EID: 0036516460     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrm763     Document Type: Review

References (104)

1. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014-1022 (1962).
2. Woessner, J. F. & Nagase, H. Matrix Metalloproteinases and TIMPs (Oxford Univ. Press, New York, 2000).
3. Barrett, A. J., Rawlings, N. D. & Woessner, J. F. Jr, Handbook of Proteolytic Enzymes (Academic, London, 1998).
4. Matrix Metalloproteinase Protocols (ed. Clark. I. M.); Methods in Molecular Biology (ed. Walker, J, M.) Vol. 151. (Humana, New Jersey. 2001).
5. Matrix Metalloproteinase Protocols (ed. Clark. I. M.); Methods in Molecular Biology (ed. Walker, J. M.) Vol. 151. (Humana, New Jersey. 2001).
6. McCawley, L. J. & Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13. 534-540 (2001).
7. Nagase, H., Barrett, A. J. & Woessner, J. F. Jr. Nomenclature and glossary of the matrix metalloproteinases. Matrix Suppl. 1, 421-424 (1992).
8. Bauer, E. A., Eisen, A. Z, & Jeffrey, J. J. Immunologic relationship of a purified human skin collagenase to other human and animal collagenases. Biochim. Biophys. Acta 206, 152-160 (1970).
9. Jeffrey, J. J. & Gross, J, Coliagenase from rat uterus isolation and partial characterization. Biochemistry 9, 268-273 (1970).
10. Roswit, W. T., Halme, J. & Jeffrey. J. J. Purification and properties of rat uterine procollagenase. Arch. Biochem. Biophys. 225, 285-295 (1983).
11. Harper, E., Bloch, K. J. & Gross, J. The zymogen of tadpole collagenase. Biochemistry 10, 3035-3041 (1971).
12. Birkedal-Hansen, H.. Cobb, C. M., Taylor, R. E. & Fullmer, H. M. Activation of latent bovine gingival collagenase. Arch. Oral Biol. 20, 681-685 (1975).
13. Van Wart, H. E. & Birkedal-Hansen, H. The cysteine switch: a principle of regulation of metaltoproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl Acad. Sci. USA 87, 5578-5582 (1990).
14. Ito, A. & Nagase, H. Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch. Biochem. Biophys. 267, 211-216 (1988).
15. Treadwell, B. V. et al. Purification and characterization of collagenase activator protein synthesized by articular cartilage. Arch. Biochem. Biophys. 251, 715-723 (1986).
16. He, C. et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl Acad. Sci. USA 88, 2632-2636 (1989).
17. Sato, H. et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-64 (1994).
18. Pei, D. & Weiss, S. J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375, 244-247 (1995).
19. Welgus, H. G. et al. A specific inhibitor of vertebrate collagenase produced by human skin fibroblasts. J. Biol. Chem. 254, 1938-1943 (1979).
20. Docherty, A. J. P. et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity, Nature 318, 66-69 (1985).
21. Gomis-Rüth, FX. et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389, 77-81 (1997).
22. Goldberg, G. I. et al. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc. Natl Acad. Sci. USA 86, 8207-8211 (1989).
23. Goldberg, G. I., Strongin, A., Collier, I. E., Genrich, L. T. & Marmer, B. L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 287, 4583-4591 (1992).
24. Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E. & Iwata, K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett. 298, 29-32 (1992).
25. Lovejoy, B. et al, Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 263, 375-377 (1994).
26. Bode, W. & Maskos, K. in Matrix Metalloproteinase Protocols (ed. Clark, I. M.) 45-77 (Humana, New Jersey, 2001).
27. Murphy, G. et al. The role of the C-terminal domain in collagenase and stromelysin specificity. J. Biol. Chem, 267, 9612-9618 (1992).
28. Hirose, T., Patterson, C., Pourmotabbed, T., Mainardi, C. L. & Hasty, K. A. Structure-function relationship of human neutrophil collagenase: identification of regions responsible for substrate specificity and general proteinase activity. Proc. Natl Acad. Sci. USA 90, 2569-2573 (1993).
29. Overall, C. M. in Matrix Metalloproteinase Protocols (ed. Clark, I. M) 79-120 (Humana, New Jersey, 2002).
30. Morgunova, E. et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed, Science 284, 1667-1670 (1999).
31. Gross, R. H., Sheldon, L. A., Fletcher, C. F. & Brinckerhoff, C. E. Isolation of a collagenase cDNA clone and measurement of changing collagenase mRNA levels during induction in rabbit synovial fibroblasts. Proc. Natl Acad. Sci. USA 81, 1981-1985 (1984).
32. Matrisian, L. M., Glaichenhaus, N., Gesnel, M. C. & Breathnach, R. Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J. 4, 1435-1440 (1985).
33. Goldberg, G. I. et al. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J. Biol. Chem. 261, 6600-6605 (1986).
34. Whitham, S. E. et al. Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem. J. 240, 913-916 (1986).
35. Matnsian, L. M. et al. The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors. Proc. Natl Acad. Sci. USA 83, 9413-9417 (1986).
36. Velasco, G. & Lopez-Otin, C. in Matrix Metalloproteinase Protocols (ed. Clark, I. M.) 25-44 (Humana, New Jersey, 2001).
37. Breathnach, R., Matrisian, L. M., Gesnel, M. C., Staub, A. & Leroy, P. Sequences coding for part of oncogene-induced transin are highly conserved in a related rat gene. Nucleic Acids Res. 15, 1139-1151 (1987).
38. Massova, I., Kotra, L P., Fridman, R. & Mobashery, S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 12, 1075-1095 (1998).
39. Collier. I. E., Bruns, G. A. P., Goldberg. G. I. & Gerhard, D. S. On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. Genomics 9, 429-434 (1991).
40. Quinn, C. O. et al, Rat collagenase cloning, amino acid sequence comparison, and parathyroid hormone regulation in osteoblastic cells. J. Biol. Chem. 265, 22342-22347 (1990).
41. Freije, J. M. R et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269, 16766-16773 (1994).
42. Balbin, M. et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 276, 10253-10262 (2001).
43. Woessner, J. F. Jr. in MMPs and TIMPs: An Historical Perspective (ed. Clark, I. M.) 1-23;
44. Methods in Molecular Biology (ed. Walker, J. M.) Vol. 151, (Humana, New Jersey, 2001).
45. Llano, E. et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors. Cancer Res. 59, 2570-2576 (1999).
46. Puente, X. S., Pendas, A. M., Llano, E., Velasco, G. & Lopez-Otin, C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 56, 944-949 (1996).
47. Itoh, Y. et al. Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. J. Biol. Chem. 274, 34260-34266 (1999).
48. Velasco, G. et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 60, 877-882 (2000).
49. Angel, P. et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49, 729-739 (1987).
50. Angel, P. et al. 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol. Cell. Biol. 7, 2256-2266 (1987).
51. Gutmann, A. & Wasylyk, B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites, EMBO J. 9, 2241-2246 (1990).
52. Benbow, U. & Brinckerhoff, C. E. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 15, 519-526 (1997).
53. Crawford, H. C. & Matrisian, L. M. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 49, 20-37 (1996).
54. Vincenti, M. P. in Matrix Metalloproteinase Protocols (ed. Clark, I. M.) 121-148 (Humana, New Jersey, 2001).
55. Ye, S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19, 623-629(2000).
56. Ye, S. et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results expression. J. Biol. Chem. 271, 13055-13060 (1996).
57. Rutter, J. L. et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 58, 5321-5325 (1998).
58. Weeks, J. G., Halme, J. & Woessner, J. E Jr. Extraction of collagenase from the involuting rat uterus. Biochim. Biophys. Acta 445, 205-214 (1976).
59. Hulboy, D. L., Rudolph, L. A. & Matrisian, L. M. Matrix metalloproteinases as mediators of reproductive function. Mol. Hum. Reprod. 3, 27-45 (1997).
60. Mudgett, J. S. et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 41, 110-121 (1998).
61. Itoh, T. et al. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J. Biol. Chem. 272, 22389-22392 (1997).
62. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L. M. & Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA 94, 1402-1407 (1997).
63. Shipley, J. M., Wesselschmidt, R. L., Kobayashi, D. K., Ley, T. J. & Shapiro, S. D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl Acad. Sci. USA 93, 3942-3946 (1996).
64. Masson, R. et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140, 1535-1541 (1998).
65. Vu, T. H. et al. MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411-422 (1998).
66. Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92 (1999).
67. Weber, B. H. F., Vogt, G., Pruett, R. C., Stohr, H. & Felbor, U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy, Nature Genet. 8, 352-356 (1994).
68. Martignetti, J. A. et al. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genet. 28, 261-265 (2001).
69. Hautamaki, R. D., Kobayashi, D. K., Senior, R. M. & Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277, 2002-2004 (1997).
70. Nelson, A. R., Fingleton, B., Rothenberg, M. L. & Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18, 1135-1149 (2000).
71. Harris, E. D. Jr, DiBona, D. R. & Krane, S. M. Collagenases in human synovial fluid. J. Clin. Invest. 48, 2104-2113 (1969).
72. Harris, E. D. Jr, DiBona, D. R. & Krane, S. M. A mechanism for cartilage destruction in rheumatoid arthritis. Trans. Assoc. Am. Physicians 83, 267-276 (1970).
73. Harris, E. D. Jr & Krane, S. M. An endopeptidase from rheumatoid synovial tissue culture. Biochim. Biophys. Acta 258, 566-576 (1972).
74. Dayer, J. M., Graham, R., Russell, G. & Krane, S. M. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 195, 181-183 (1977).
75. Firestein, G. in Textbook of Rheumatology (eds Kelley, W., Harris, E. D. J., Ruddy, S. & Sledge, S.) 851-897 (W. B. Saunders, Philadelphia, 1997).
76. Liotta, L. A. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68 (1980).
77. Sternlicht, M. D. & Bergers, G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Therapeutic Targets 4, 609-633 (2000).
78. Basset, P. et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348, 699-704 (1990).
79. Koop, S. et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. CancerRes. 54, 4791-4797 (1994).
80. Stetler-Stevenson, W. G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103, 1237-1241 (1999).
81. Whittaker, M., Floyd, C. D., Brown, P. & Gearing, A. J. H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735-2776 (1999).
82. Reich, R. et al. Inhibitors of collagenase IV and cell adhesion reduce the invasive activity of malignant tumour cells. Ciba Found. Symp. 141, 193-210 (1988).
83. Brown, P. D., Davidson, A. H., Drummond, A. H., Gearing, A. & Whittaker, M. in Matrix Metalloproteinase Inhibitors in Cancer Therapy (eds Clendeninn, N. J. & Appelt, K.) 113-142 (Humana, New Jersey, 2001).
84. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinases: trials and tribulations. Science (in the press).
85. Wynn, R. L. Latest FDA approvals for dentistry. Gen. Dent. 47, 19-22 (1999).
86. Edwards, D. R. et al. Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6, 1899-1904 (1987).
87. Kerr, L. D., Miller, D. B. & Matrisian, L. M. TGF-β1 inhibition of transin-stromelysin gene expression is mediated through a los fos binding sequence. Cell 61, 267-278 (1990).
88. Uria, J. A., Jimenez, M. G., Balbin, M., Freije, J. M. & Lopez-Otin, C. Differential effects of transforming growth factor-β on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J. Biol. Chem. 273, 9769-9777 (t998).
89. White, L. A., Mitchell, T. I. & Brinckerhoff, C. E. Transforming growth factor β inhibitory element in the rabbit matrix metalloproteinase-1 (collagenase-1) gene functions as a repressor of constitutive transcription. Biochim. Biophys. Acta 1490, 259-268 (2000).
90. Jonat, C. et al. Anti-tumor promotion and anti-inflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62, 1189-1204 (1990).
91. Yang-Yen, H. F. et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62, 1205-1215 (1990).
92. Schüle, R. et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62, 1217-1226(1990).
93. Brinckerhoff, C. E., McMillan, R. M., Dayer, J. M. & Harris, E. D. Jr. Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. N. Engl. J. Med. 303, 432-436 (1980).
94. Nicholson, R. C. et al. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J. 9, 4443-4454 (1990).
95. Schule, R. et al. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc. Natl Acad. Sci. USA 88, 6092-6096 (1991).
96. Fisher, G. J. et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 379, 335-339 (1996).
97. Fisher, G. J. et al. Pathophysiology of premature skin aging induced by ultraviolet light. N. Engl. J. Med. 337, 1419-1428 (1997).
98. Lala, D. S. et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383, 450-453 (1996).
99. Spanjaard. R. A. et al. Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARγ in induction of differentiation and apoptosis of S91 melanoma cells. J. Biol. Chem. 272, 18990-18999 (1997).
100. Mix, K. S. et al. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 44, 1096-1104 (2001).
101. Galardy. R. E. et al. Low molecular weight inhibitors in corneal ulceration. Ann. NY Acad. Sci. 732, 315-323 (1994).
102. British Biotech PLC. http://www.britishbiotech.com/product.htm.2002.
103. Gross, J. & Nagai, Y. Specific degradation of the collagen molecule by tadpole collagenolytic enzyme. Proc. Natl Acad. Sci. USA 54, 1197-1204 (1965).
104. Itoh, Y. et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 20, 4782-4793 (2001).